Latest Regulatory Compliance News

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.

Coronado Global Resources has finalised a US$150 million secured lending facility to bolster its liquidity, supporting ongoing expansion and cost-saving efforts amid a tough coal market.

BetMakers Technology Group has launched a $1 million Share Purchase Plan (SPP) at $0.10 per share, offering eligible shareholders in Australia and New Zealand a chance to increase holdings at a discount following a $12.5 million institutional placement.

Harvest Technology Group reports it is one year ahead of its 3-Year Pathway to Profit plan, forecasting a significant reduction in EBITDA loss for FY25 and unveiling plans for its AI-powered NEON platform launch in 1H26.

Koba Resources has completed a $600,000 placement of shares at 3.6 cents each, sweetened with free options exercisable at 8 cents until mid-2028. The move strengthens the company’s capital base without triggering extensive disclosure requirements.

Astron Corporation is set to redomicile from Hong Kong to Australia, establishing a new Australian parent company and simplifying shareholder engagement. This move aims to align governance with local standards and boost investor confidence.

Western Gold Resources has confirmed a binding toll milling agreement with Wiluna Mining Corporation, explaining recent unusual trading activity in its shares.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Marimaca Copper has successfully closed the second tranche of a US$17.7 million private placement, bolstering funds to advance its flagship copper project in Chile. This capital injection marks a significant step in progressing the Marimaca Copper Project’s feasibility and exploration activities.

Macarthur Minerals has clarified key details regarding its recent convertible note funding, confirming the counterparty is an independent entity and highlighting the need for shareholder approval before issuing shares on conversion.